FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379647494> ?p ?o ?g. }

• W4379647494 endingPage "1810" @default.
• W4379647494 startingPage "1809.2" @default.
• W4379647494 abstract "Background The Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4), culturally adapted to Spanish language following the standardized methodology, [1] was recommended by experts due to the reduced number of items, [2] its high sensitivity/specificity and the feasibility to implement in clinical practice. Objectives To confirm the presence/absence of psoriatic arthritis (PsA) according to rheumatologist criteria in patients (pts) with psoriasis (Pso) 1 year after having answered the PURE-4 questionnaire in the dermatology consultation. Methods Cross-sectional, observational, multicenter study conducted with primary data collection under conditions of routine clinical practice in Spain. Adult pts (≥18 years old) with Pso diagnosis that voluntarily accepted to participate. Two cross-sectional evaluations. Assessment I allowed to validate the Spanish version of the PURE-4 questionnaire and its results were previously communicated. [3] Data from assessment II (pts without PsA in assessment I were evaluated by the rheumatologist 1 year ±2 months later and performed the PsA diagnostic confirmation according to her/his criteria and collected clinical characteristics) are presented here. Results 268 patients pts were included in assessment I, 223 (83.2%) of them without a PsA diagnosis. 219 pts were evaluable in assessment II, as they go to the second visit to rheumatologist: 56.2% male, with a mean (SD) age of 46.8 (12.5) years, a mean (SD) time from Pso diagnosis of 18.7 (12.8) years. Mean (SD) PURE-4 score was 2.4 (1.1) for pts with PsA and 1.2 (1.2) for pts without PsA diagnosis. Among pts who did assessment II, PsA diagnosis was confirmed in 12 (5.5%) pts. Area under the receiver-operating characteristic (ROC) curve was 0.7618 (95% CI: 0.6530, 0.8706) (n=217), confirming the good quality of the questionnaire (Figure 1). Using the Youden index, it was identified a score ≥2 indicative of a possible early presence of PsA, same as in assessment I. PURE-4 questionnaire showed a sensitivity of 75.0% and a specificity of 62.9%. In 63.6% of the cases, the PURE-4 questionnaire classified pts in the same way as the rheumatologist, with a negative predictive value of 97.7%. Conclusion Assessment II findings together with the assessment I results, demonstrate the good PsA screening properties of the PURE-4 questionnaire, starting with a ≥2 score, differing from the original questionnaire (≥1). [4] Questions of the PURE-4 questionnaire referring to dactylitis, both buttocks pain and peripheral joint pain with swelling (before age 50) were the most “discriminative” of PsA. The study reinforce the recommendation to assess annually, or ideally every 6 months, the possible PsA presence, [5] as early PsA identification thanks to simple tools such as PURE-4 could help to prevent irreversible joint damage of this disease. References [1]Belinchón I, et al. Actas Dermosifiliogr. 2020;111(8):655-64. [2]Urruticoechea-Arana A, et al. PLoS One. 2021;16(3): e0248571. [3]Queiro Silva R, et al. Ann Rheum Dis. 2022;81:862-3. [4]Audureau E, et al. J Eur Acad Dermatol Venereol. 2018;32(11):1950-3. [5]Belinchón I, et al. Actas Dermosifiliogr. 2020;111(10):835-46. Figure 1. Area under the ROC curve (assessment II) AUC, area under the curve; Se, sensitivity; Sp, specificity. Acknowledgements The authors thank IQVIA and Carmen Barrull and Marco Pinel for providing medical editorial assistance with this presentation. Disclosure of Interests Rubén Queiró Silva Grant/research support from: received honoraria as part of the scientific committee of the PURE-4 study, Isabel Belinchón Speakers bureau: consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB and MSD, Consultant of: consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB and MSD, Grant/research support from: consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen, Amgen, Leo-Pharma, Pfizer-Wyeth, BMS, UCB and MSD, Anna Lopez-Ferrer Speakers bureau: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Consultant of: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Grant/research support from: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Marta Ferran i Farrés Speakers bureau: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Consultant of: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Grant/research support from: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Raquel Rivera Díaz Speakers bureau: consultant, researcher and/or speaker for AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer and UCB, Consultant of: consultant, researcher and/or speaker for AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer and UCB, Grant/research support from: consultant, researcher and/or speaker for AbbVie, Almirall, Celgene Corporation, GSK, Janssen-Cilag, Lilly, LEO Pharma, MSD, Novartis, Pfizer and UCB, David Vidal Sarro Speakers bureau: advisor and/or researcher and/or speaker for AbbVie, Janssen, Lilly, Novartis and UCB, Consultant of: advisor and/or researcher and/or speaker for AbbVie, Janssen, Lilly, Novartis and UCB, Grant/research support from: advisor and/or researcher and/or speaker for AbbVie, Janssen, Lilly, Novartis and UCB, lourdes rodriguez freire Speakers bureau: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer and UCB, Consultant of: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer and UCB, Grant/research support from: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer and UCB, Pablo de la Cueva Dobao Speakers bureau: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Consultant of: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Grant/research support from: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, BMS, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Jorge Santos Juanes Speakers bureau: speaker for, received scholarships, and participated in advisory sessions for Novartis, Lilly, Janssen, Abbvie, Amgen, and Sanofi, Consultant of: speaker for, received scholarships, and participated in advisory sessions for Novartis, Lilly, Janssen, Abbvie, Amgen, and Sanofi, Grant/research support from: speaker for, received scholarships, and participated in advisory sessions for Novartis, Lilly, Janssen, Abbvie, Amgen, and Sanofi, Vicenç Rocamora Duran Speakers bureau: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Consultant of: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Grant/research support from: advisor and/or researcher and/or speaker for Abbvie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Guillermo Guinea Uzábal Employee of: Novartis employee, Víctor Martín Vázquez Employee of: Novartis employee, Lara Gómez Labrador Employee of: Novartis employee." @default.
• W4379647494 created "2023-06-08" @default.
• W4379647494 creator A5012791480 @default.
• W4379647494 creator A5040539034 @default.
• W4379647494 creator A5052756358 @default.
• W4379647494 creator A5055662811 @default.
• W4379647494 creator A5057287194 @default.
• W4379647494 creator A5063680659 @default.
• W4379647494 creator A5068581445 @default.
• W4379647494 creator A5068976668 @default.
• W4379647494 creator A5069050196 @default.
• W4379647494 creator A5072784314 @default.
• W4379647494 creator A5081127822 @default.
• W4379647494 creator A5087676541 @default.
• W4379647494 creator A5091332126 @default.
• W4379647494 date "2023-05-30" @default.
• W4379647494 modified "2023-10-16" @default.
• W4379647494 title "AB1159 THE SPANISH VERSION OF THE PURE-4 QUESTIONNAIRE USE FOR PSORIATIC ARTHRITIS SCREENING AFTER 1 YEAR OF FOLLOW-UP IN PATIENTS WITH PSORIASIS" @default.
• W4379647494 doi "https://doi.org/10.1136/annrheumdis-2023-eular.3472" @default.
• W4379647494 hasPublicationYear "2023" @default.
• W4379647494 type Work @default.
• W4379647494 citedByCount "0" @default.
• W4379647494 crossrefType "journal-article" @default.
• W4379647494 hasAuthorship W4379647494A5012791480 @default.
• W4379647494 hasAuthorship W4379647494A5040539034 @default.
• W4379647494 hasAuthorship W4379647494A5052756358 @default.
• W4379647494 hasAuthorship W4379647494A5055662811 @default.
• W4379647494 hasAuthorship W4379647494A5057287194 @default.
• W4379647494 hasAuthorship W4379647494A5063680659 @default.
• W4379647494 hasAuthorship W4379647494A5068581445 @default.
• W4379647494 hasAuthorship W4379647494A5068976668 @default.
• W4379647494 hasAuthorship W4379647494A5069050196 @default.
• W4379647494 hasAuthorship W4379647494A5072784314 @default.
• W4379647494 hasAuthorship W4379647494A5081127822 @default.
• W4379647494 hasAuthorship W4379647494A5087676541 @default.
• W4379647494 hasAuthorship W4379647494A5091332126 @default.
• W4379647494 hasBestOaLocation W43796474941 @default.
• W4379647494 hasConcept C126322002 @default.
• W4379647494 hasConcept C16005928 @default.
• W4379647494 hasConcept C2776260265 @default.
• W4379647494 hasConcept C2777077863 @default.
• W4379647494 hasConcept C2780564577 @default.
• W4379647494 hasConcept C71924100 @default.
• W4379647494 hasConceptScore W4379647494C126322002 @default.
• W4379647494 hasConceptScore W4379647494C16005928 @default.
• W4379647494 hasConceptScore W4379647494C2776260265 @default.
• W4379647494 hasConceptScore W4379647494C2777077863 @default.
• W4379647494 hasConceptScore W4379647494C2780564577 @default.
• W4379647494 hasConceptScore W4379647494C71924100 @default.
• W4379647494 hasIssue "Suppl 1" @default.
• W4379647494 hasLocation W43796474941 @default.
• W4379647494 hasOpenAccess W4379647494 @default.
• W4379647494 hasPrimaryLocation W43796474941 @default.
• W4379647494 hasRelatedWork W1566732118 @default.
• W4379647494 hasRelatedWork W1973094410 @default.
• W4379647494 hasRelatedWork W1998912255 @default.
• W4379647494 hasRelatedWork W2114372554 @default.
• W4379647494 hasRelatedWork W2167905575 @default.
• W4379647494 hasRelatedWork W2304821432 @default.
• W4379647494 hasRelatedWork W2399108082 @default.
• W4379647494 hasRelatedWork W2399171524 @default.
• W4379647494 hasRelatedWork W2417900408 @default.
• W4379647494 hasRelatedWork W2518783584 @default.
• W4379647494 hasVolume "82" @default.
• W4379647494 isParatext "false" @default.
• W4379647494 isRetracted "false" @default.
• W4379647494 workType "article" @default.